Lundberg et al. [135] determined CCND1 amplification and its association with worst 15-year survival with ER+/LN−/HER2−(1.66; 1.14–2.41), luminal A (HR = 1.68; 95% CI, 1.15–2.46), and luminal B (1.37; 1.01–1.86) breast cancer subtypes [135]. This evidence concerns the gene ESR1 and breast carcinoma.